TOPIC:

Here are the available studies as they relate to GT1 and Sof+Led (Harvoni) vs Sof+Dac (Sovaldi + Dalinza)

Sof+Dac

GT1 ALLY-2 naive (80/83) experienced (43/44) Aggregate 96.8% (123/127)
GT1a ALLY-2 naive 96% (68/71) experienced 97% (32/33) Aggregate 96.2% (100/104)
GT1b ALLY-2 ALLY-2 naive 100% (12/12) experienced 100% (11/11) Aggregate 100% (23/23)
F4 ALLY-2 naive 89% (8/9) experienced 92% (12/13) Aggregate 90.9% (20/22)
Past Failure ALLY-2 98% (43/44)

Sof+Led

GT1 ION-1 98% (142/145) ION-3 96% 96% (165/172) Aggregate 96.8% (307/317)
GT1a ION-1 98% (142/145) ION-3 96% 96% (165/172) Aggregate 96.8% (307/317)
GT1b ION-1 100% (67/67) ION-3 98% (43/44) Aggregate 99.1% (110/111)
F4 ION-1 97% (32/33)
Past Failure ON-3 94% (102/109)

Not a lot between them, but the data for Sof+Led is more robust due to better n

I would be happy taking either. Sof+Dac is a better choice if taking antacid type medications because Ledipasvir needs acid for absorption.

What acid does Ledipasvir need ?

Stomach acid in which some have too much hence the use of antacids etc.

Do u have led vs dac data for redemption trial doc? Both equal in efficacy?

If I understood correctly, Dac is just slightly better than Led in types 1 and 4. And we already knew that type 3 has to use Dac.

So the evidence is in ...

Daclatasvir is the pan-genotypic choice.

And now AbbVie is getting high success rates WITHOUT Sofosbuvir !!!
www.prnewswire.com/news-releases/abbvies...irals-300252074.html

Let the price competition begin!

Hi I am a bit confused about both what DAAs combination and length of tx are best for:
Genotype 1b
VL 1.200.000
Tx Naive
F0 - F1
ALT and other enzymes levels on the higher end of normal.

What is the criteria for either 8 weeks tx versus 12 weeks? Thank you.

Hi Meg,

With Harvoni and your profile - 1b, naive, low fibrosis, low viral load (<6 million) the evidence is that 8 weeks treatment is just as effective as 12.

You could do 12 for insurance/reassurance, but you fit the shorter treatment profile and using it would save you $500

Thank you!
Eight weeks tx feels like very good news!

Treatment of GT1 in Denmark: Genotype 1 without cirrhosis

Hi James Freemann

For your information:

(1st choice to min. 70% of
Population) February 2017

Here is what the Danish health authorities recommend if they are offered treatment in Denmark

Viekirax® (ombitasvir 12.5 mg + paritaprevir
75 mg + ritonavir 50 mg) 2 tablets 1 x
Daily for 12 weeks
+
Exviera® (dasabuvir 250 mg) 2 x daily in 12
weeks
+
Ribavirin 2 x daily for 12 weeks


Before, there were 6 different treatment proposals, all of which were equal:

Genotype 1 without cirrhosis
Use as 1st choice for
mine. 70% off
population
(Genotype 1) Sep 2016:
(Strong recommendation for)
Sofosbuvir (400 mg) + ledipasvir (90 mg) 1 x daily
For 8-12 weeks *
or
Sofosbuvir 1 x daily (400 mg) and simprevir 1 x daily
(150 mg) for 12 weeks
or
Sofosbuvir 1 x daily (400 mg) and daclatasvir 1 x daily
(60 mg) for 12 weeks
or
Ombitasvir (12.5 mg) + paritaprevir (75 mg) + ritonavir
(50 mg) 2 tablets 1 x daily and dasabuvir (250 mg)
2 x daily for 12 weeks **
or
Sofosbuvir (400 mg) + velpatasvir (100 mg) 1 x daily
For 12 weeks
or
Elbasvir (50 mg) + grazoprevir (100 mg) 1 x daily for 12
week ***

Greeting
Gert

Hi Meg,

With Harvoni and your profile - 1b, naive, low fibrosis, low viral load (<6 million) the evidence is that 8 weeks treatment is just as effective as 12.

You could do 12 for insurance/reassurance, but you fit the shorter treatment profile and using it would save you $500

Since writing this new evidence has come to light.

fixhepc.com/forum/experts-corner/1576-8-...2-weeks-harvoni.html

In short, 8 weeks is probably a bad choice unless you are very strapped financially, fit the profile and simply can't afford 12.